BioMarker Strategies earns SBIR grant
This article was originally published in The Gray Sheet
Executive Summary
Firm is awarded a $254,000 Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute to develop its SnapPath live-tumor-cell testing system, designed to help oncologists determine the most effective course of drug treatment for their patients. The contract allows an additional $2 million in SBIR funding once the phase one work is complete, the company notes in an Oct. 7 press release
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.